Daily Cardiology Research Analysis
Analyzed 200 papers and selected 3 impactful papers.
Summary
Analyzed 200 papers and selected 3 impactful articles.
Selected Articles
1. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
In 779 analyzable patients randomized to sodium bicarbonate or placebo during in-hospital cardiac arrest, sustained ROSC occurred in 39% vs 37% (RR 1.05; P=0.62). Thirty-day survival and favorable neurologic outcomes were not significantly different, while alkalosis and hypernatremia were more frequent with bicarbonate. Routine bicarbonate use during in-hospital cardiac arrest is not supported.
Impact: High-quality RCT in a top journal provides definitive evidence against a ubiquitous resuscitation practice, preventing low-value and potentially harmful therapy.
Clinical Implications: Do not routinely administer sodium bicarbonate during in-hospital cardiac arrest unless there is a specific indication (e.g., hyperkalemia, tricyclic overdose). Emphasize guideline-directed care focusing on high-quality CPR, timely defibrillation, and appropriate vasopressor use.
Key Findings
- Sustained ROSC: 39% with sodium bicarbonate vs 37% with placebo (RR 1.05; 95% CI 0.88–1.24; P=0.62).
- Thirty-day survival: 12% vs 9.1% (RR 1.25; 95% CI 0.84–1.88), not statistically significant.
- Higher rates of alkalosis and hypernatremia in the bicarbonate group post-arrest.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled design with prespecified outcomes.
- Adequate sample size and pragmatic enrollment across 21 hospitals enhancing external validity.
Limitations
- Study powered for ROSC; secondary outcomes (neurologic status) may be underpowered.
- Generalizability limited to in-hospital cardiac arrest; out-of-hospital settings not addressed.
Future Directions: Refine indications for bicarbonate in specific metabolic derangements; evaluate targeted buffering strategies guided by blood gas/metabolomics; investigate interactions with vasopressors and ventilation strategies.
IMPORTANCE: Patients with in-hospital cardiac arrest have poor outcomes. Sodium bicarbonate is commonly administered during cardiac arrest, but the effects on clinical outcomes are unknown. OBJECTIVE: To determine whether administration of sodium bicarbonate during in-hospital cardiac arrest increases the proportion of patients with return of spontaneous circulation. DESIGN, SETTING, AND PARTICIPANTS: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted at 21 hospitals in Denmark. Participants were adults with in-hospital cardiac arrest, who received at least 1 dose of epinephrine. Patients were enrolled from February 6, 2023, to February 11, 2026, with the last 90-day follow-up conducted on May 4, 2026. Final statistical analysis was conducted on May 5, 2026. INTERVENTION: Sodium bicarbonate (up to 100 mmol) or placebo intravenously. MAIN OUTCOMES AND MEASURES: The primary outcome was sustained return of spontaneous circulation. Key secondary outcomes were survival at 30 days and survival at 30 days with a favorable neurologic outcome, defined by a score of 0 to 3 on the modified Rankin Scale (scores range from 0 to 6, with higher scores indicating greater disability).
2. Histaminylation alters collagen matrix mechanics and attenuates cardiac fibrosis post-myocardial infarction via mechanotransduction signaling axis.
This mechanistic study identifies histaminylation of cardiac type I collagen post-MI and links this modification to altered collagen mechanics and attenuation of fibrosis through a mechanotransduction signaling axis. The modification is catalyzed by TGM2 and was detected by mass spectrometry 7 days after MI; histamine deficiency was leveraged to probe pathway dependence.
Impact: Revealing a novel, druggable post-translational modification of the cardiac extracellular matrix that modulates fibrosis could redefine anti-fibrotic strategies after MI.
Clinical Implications: While preclinical, targeting TGM2-mediated histaminylation or downstream mechanotransduction could yield anti-fibrotic therapies to improve post-MI remodeling and heart failure outcomes.
Key Findings
- Histaminylation of cardiac type I collagen was identified 7 days after MI by mass spectrometry.
- This modification is catalyzed by transglutaminase 2 (TGM2).
- Histaminylation altered collagen matrix mechanics and attenuated post-MI fibrosis via a mechanotransduction signaling axis.
- Histamine-deficient (Hdc) context was used to interrogate pathway dependence.
Methodological Strengths
- Use of mass spectrometry to directly identify a novel post-translational modification in vivo
- Integration of mechanistic signaling (mechanotransduction) with matrix biomechanics in a disease-relevant MI model
Limitations
- Findings are preclinical and primarily derived from murine models
- Extent of translatability and safety of targeting TGM2/histaminylation in humans remains to be established
Future Directions: Validate histaminylation signatures in human post-MI tissue, define upstream regulators and downstream effectors of mechanotransduction, and test pharmacologic modulators of TGM2/histaminylation in large-animal models.
Histaminylation is a newly discovered monoaminylation catalyzed by transglutaminase 2 (TGM2), and its role in myocardial fibrosis has not yet been elucidated. Here, we identified histaminylation in cardiac type I collagen isolated from mice 7 days after acute myocardial infarction (AMI) by mass spectrometry. Using histamine-deficient Hdc
3. AAV-mediated long-term TBX18 expression causes cardiac fibrosis and fails to induce pacemaker activity in rodents.
Long-term AAV-mediated TBX18 expression caused severe cardiac fibrosis and failed to induce pacemaker activity, even at non-fibrogenic levels. In contrast, AAV-Hcn2 produced robust ectopic pacing in an AV block rat model. These results overturn prior short-term observations and redirect biological pacemaker development toward ion channel–based strategies.
Impact: Provides rigorous mechanistic and safety data that contradict a prominent approach to biological pacing, prioritizing alternative targets (Hcn2) with better translational potential.
Clinical Implications: TBX18 should not be advanced toward clinical biological pacemaker trials; Hcn2 or other ion channel–based constructs warrant further preclinical development with careful long-term safety profiling.
Key Findings
- CMV-driven cardiac TBX18 overexpression induced severe myocardial fibrosis in mice.
- At lower expression, TBX18 suppressed working myocardial genes but did not activate a pacemaker gene program; funny current (If) was absent.
- In AV-block rats, AAV-Hcn2 induced robust ectopic pacemaker activity (with isoproterenol), whereas TBX18 failed and did not augment Hcn2 pacing.
Methodological Strengths
- Head-to-head comparison of TBX18 and Hcn2 across complementary in vivo models with electrophysiology and histology.
- Assessment of both efficacy and fibrosis-related safety with promoter-dependent expression control.
Limitations
- Rodent models may not fully recapitulate human cardiac conduction system biology.
- Promoter choice and AAV serotype may influence translatability; off-target and dose–response not exhaustively mapped.
Future Directions: Advance ion channel–based biological pacemakers (e.g., Hcn2) with tissue-specific promoters, tunable expression, and long-term arrhythmia surveillance; explore combinatorial strategies (e.g., gap junction modulation) and large-animal validation.
Gene therapy-based biological pacemakers have been proposed as an alternative to their hardware-based counterparts. In this context, short-term ectopic expression of the T-box transcription factor 18 (TBX18) in the ventricle has been reported to generate potent short-term pacemaker function in various animal models. Here, we investigated the impact of adeno-associated virus (AAV)-mediated long-term expression of TBX18, and compared the outcomes to those of the pacemaker ion channel Hcn2. Our findings revealed that CMV-driven ectopic TBX18 expression in mouse hearts led to severe cardiac fibrosis. At lower, non-fibrogenic levels, TBX18 maintained its transcriptional function but failed to induce pacemaker phenotypes. TBX18-expressing cells showed suppressed expression of key working myocardial genes, but the pacemaker gene program was not induced. Electrophysiological studies showed abnormal automaticity in TBX18-expressing cells, combined with prolonged repolarization and various current changes. However, no hyperpolarization-activated funny current was detected. In a complete AV-block rat model, AAV-mediated Hcn2 expression induced robust ectopic pacemaker activity in the presence of isoproterenol, whereas TBX18 expression neither generated such activity nor augmented Hcn2-mediated pacing. In conclusion, at functionally non-fibrogenic levels, TBX18 is neither sufficient nor necessary to induce pacemaker activity. In contrast, Hcn2 generates reliable pacing, making it a more viable candidate for biological pacemaker development.